Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
Agios Pharmaceuticals (AGIO), a company focused on cellular metabolism and pyruvate kinase activation therapies for rare diseases, has announced it will host a conference call and live webcast to discuss its fourth quarter and full year 2024 financial results. The event is scheduled for Thursday, February 13, 2025, at 8:00 a.m. ET. The webcast will be available on the company's website under the Investors section, with a replay accessible approximately two hours after the event.
Agios Pharmaceuticals (AGIO), un'azienda specializzata in terapie per il metabolismo cellulare e l'attivazione della piruvato chinasi per malattie rare, ha annunciato che organizzerà una conferenza telefonica e una diretta streaming per discutere i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024. L'evento è programmato per giovedì 13 febbraio 2025, alle 8:00 ET. La diretta sarà disponibile sul sito web dell'azienda nella sezione Investitori, con una registrazione accessibile circa due ore dopo l'evento.
Agios Pharmaceuticals (AGIO), una compañía centrada en terapias para el metabolismo celular y la activación de la piruvato quinasa para enfermedades raras, ha anunciado que llevará a cabo una conferencia telefónica y una transmisión en vivo para discutir sus resultados financieros del cuarto trimestre y del año completo 2024. El evento está programado para el jueves 13 de febrero de 2025, a las 8:00 a.m. ET. La transmisión estará disponible en el sitio web de la compañía en la sección de Inversores, con una repetición accesible aproximadamente dos horas después del evento.
Agios Pharmaceuticals (AGIO)는 희귀 질병을 위한 세포 대사 및 피루베이트 키나제 활성화 요법에 중점을 둔 회사로, 2024년 4분기 및 연간 재무 실적을 논의하기 위한 컨퍼런스 콜 및 라이브 웹캐스트를 개최한다고 발표했습니다. 이 행사는 2025년 2월 13일 목요일, 오전 8시 ET로 예정되어 있습니다. 웹캐스트는 회사 웹사이트의 투자자 섹션에 제공되며, 이벤트 후 약 두 시간 뒤에 다시 볼 수 있습니다.
Agios Pharmaceuticals (AGIO), une entreprise spécialisée dans le métabolisme cellulaire et les thérapies d'activation de la pyruvate kinase pour les maladies rares, a annoncé qu'elle organiserait une conférence téléphonique et un webinaire en direct pour discuter de ses résultats financiers du quatrième trimestre et de l'année complète 2024. L'événement est prévu pour jeudi 13 février 2025, à 8h00 ET. Le webinaire sera disponible sur le site web de l'entreprise dans la section Investisseurs, avec un replay accessible environ deux heures après l'événement.
Agios Pharmaceuticals (AGIO), ein Unternehmen, das sich auf Zellstoffwechsel und Therapien zur Aktivierung der Pyruvatkinase für seltene Krankheiten konzentriert, hat angekündigt, eine Telefonkonferenz und einen Live-Webcast abzuhalten, um über seine Finanzberichte für das vierte Quartal und das gesamte Jahr 2024 zu diskutieren. Die Veranstaltung ist für Donnerstag, den 13. Februar 2025, um 8:00 Uhr ET geplant. Der Webcast wird auf der Website des Unternehmens im Bereich Investoren verfügbar sein, wobei eine Wiederholung etwa zwei Stunden nach der Veranstaltung zugänglich ist.
- None.
- None.
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 13, 2025, at 8:00 a.m. ET to report its fourth quarter and full year 2024 financial results and business highlights.
The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndrome (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com
FAQ
When will Agios (AGIO) report Q4 and full year 2024 earnings?
How can investors access AGIO's Q4 2024 earnings call?
Will AGIO's Q4 2024 earnings call be available for replay?
What will Agios (AGIO) discuss in their February 13, 2025 conference call?
